文献速递生殖医学

植入前非整倍体遗传学检测已走到尽头

We have reached a dead end for preimplantation genetic testing for aneuploidy.
PubMed 文献 · Hum Reprod · 2022-01-01

本文回顾了植入前非整倍体遗传学检测(PGT-A)20年来的证据,指出两项符合要求的随机对照试验经正确分析后未显示PGT-A的显著优势,反而在纠正患者选择偏倚后显示结局更差;且囊胚期高嵌合率导致大量正常胚胎被弃用,作者强烈呼吁将PGT-A限制于研究方案。

要点

  • 两项符合要求的随机对照试验经正确分析后未显示PGT-A的显著优势。
  • 纠正偏向PGT-A的患者选择偏倚后,PGT-A组结局反而更差。
  • 囊胚期高嵌合率导致大量染色体正常胚胎被不必要地弃用。

核心结论

  • 作者强烈呼吁将PGT-A限制于研究方案,并鼓励专业学会制定相应实践指南。

研究设计与样本

  • 本文为观点性文章,回顾了PGT-A的假说及后续证据,包括两项评估单次取卵后累计活产率的随机对照试验。

主要发现

  • 两项随机对照试验经正确分析后不仅未显示PGT-A的显著优势,反而在纠正偏向PGT-A的患者选择偏倚后显示结局更差。
  • 囊胚期高嵌合率导致滋养层活检假阳性率高,大量染色体正常且具有正常妊娠潜能的胚胎被不必要地弃用或丢弃。

临床怎么用

  • 作者强烈呼吁将PGT-A限制于研究方案,并鼓励专业学会制定相应实践指南。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The hypothesis of preimplantation genetic testing for aneuploidy (PGT-A) was first proposed 20 years ago, suggesting that during IVF elimination of aneuploid embryos prior to transfer will improve implantation rates of remaining embryos and, therefore, increase pregnancy and live birth rates, while also reducing miscarriages. Subsequently, unvalidated and increasingly unrestricted clinical utilization of PGT-A called for at least one properly randomized controlled trial (RCT) to assess cumulative live birth rates following a single oocyte retrieval, utilizing all fresh and frozen embryos of an IVF cycle. Only recently two such RCTs were published, however both, when properly analysed, not only failed to demonstrate significant advantages from utilization of PGT-A, but actually demonstrated outcome deficits in comparison to non-use of PGT-A, when patient selection biases in favour of PGT-A were reversed. Moreover, because of high embryo mosaicism at the blastocyst stage and, therefore, high false-positive rates from trophectoderm biopsies, large numbers of chromosomal-normal embryos with normal pregnancy potential are unnecessarily left unused or discarded, indisputably causing harm to affected couples. We, therefore, strongly call for restricting PGT-A to only research protocols and, as of this point in time, encourage professional societies in the field to follow suit with appropriate practice guidelines.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Gleicher N, Barad DH, Patrizio P, et al. We have reached a dead end for preimplantation genetic testing for aneuploidy. Hum Reprod. 2022. PMID: 35355062. doi:10.1093/humrep/deac052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。